JCV-specific TCR a chains-CD3zeta fusion protein (Roger Williams Medical Center)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameJCV-specific TCR a chains-CD3zeta fusion protein (Roger Williams Medical Center)

Drug Alias Nameanti-JCV TCR-based chimeric immune receptors (Roger Williams Medical Center)functional designer T cells therapy (Roger Williams Medical Center)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionNeuroprotectants

TargetsUpdating

Therapy Area/IndicationsLeukoencephalopathy, Progressive Multifocal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRoger Williams Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRoger Williams Medical Center

Active IndicationsN/A

Inactive IndicationsLeukoencephalopathy, Progressive Multifocal

Other Information

ATC CodeN/A